Table 4 Evolution of quality indicators as formulated by EUSOMA prospectively evaluated between 2003 and 2010 (data for first semester)
Outcome measure | 2003 | 2010 | P value | ||||
|---|---|---|---|---|---|---|---|
EUSOMA | |||||||
Minimum standard | Target | N | % | N | % | ||
Positive preoperative cyto/histological diagnosis | 77/130 | 59.7% | 161/183 | 88.4% | 0.0001 | ||
80% | 90% | ||||||
Operated invasive carcinoma for which hist. type, grading ER/PR, stage and size were recorded | 106/112 | 94.6% | 178/181 | 98.3% | 0.1467 | ||
90% | 95% | ||||||
Operated non invasive carcinoma for which size, histological type and grading are recorded | 5/7 | 71% | 28/29 | 96.5% | 0.4966 | ||
95% | 98% | ||||||
More than 9 lymph nodes removed when ALD performed (excluding sampling) | 97/112 | 85.6% | 67/70 | 95.7% | 0.0434 | ||
95% | 98% | ||||||
Postoperative radiotherapy in M0 invasive CA with BCT | 50/51 | 98% | 105/108 | 97.2% | 0.7588 | ||
90% | 95% | ||||||
BCT in invasive carcinoma with total size up to 30 mm (including DCIS component) | 49/79 | 62% | 86/104 | 82.6% | 0.0016 | ||
70% | 80% | ||||||
BCT in carcinoma in situ up to 20 mm | 3/7 | 43.8% | 11/14 | 78.6 | 0.0016 | ||
70% | 80% | ||||||
Ductal carcinoma in situ without axillary dissection | 6/7 | 85.7% | 22/23 | 95.6% | 0.3560 | ||
80% | 90% | ||||||
Hormonotherapy in endocrine sensitive invasive carcinoma | 89/105 | 84.8% | 151/155 | 97.4% | 0.0002 | ||
80% | 90% | ||||||
Adjuvant chemotherapy in ER- (PT1c+ or N+) invasive Carcinoma | 18/25 | 72% | 22/23 | 95.6% | 0.0280 | ||
80% | 90% |